Krystal Biotech, Inc. (KRYS) Tops Q4 EPS by 59c

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of $0.30, $0.59 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $42.1 million versus the consensus estimate of $28.61 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion
• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside